Literature DB >> 11745266

Intravenous methadone in the management of chronic cancer pain: safe and effective starting doses when substituting methadone for fentanyl.

J Santiago-Palma1, N Khojainova, C Kornick, D J Fischberg, L H Primavera, R Payne, P Manfredi.   

Abstract

BACKGROUND: Patients often are rotated from other opioids to methadone when side effects occur before satisfactory analgesia is achieved. Various strategies have been proposed to estimate safe and effective starting doses of methadone when rotating from morphine and hydromorphone; however, there are no guidelines for estimating safe and effective starting doses of methadone when rotating from fentanyl.
METHODS: The authors prospectively observed 18 consecutive patients experiencing chronic pain from cancer who underwent opioid rotation from intravenous patient-controlled analgesia (PCA) with fentanyl to intravenous PCA with methadone. Patients were switched from fentanyl to methadone because of uncontrolled pain associated with sedation or confusion. A conversion ratio of 25 microg/hour of fentanyl to 0.1 mg/hour of methadone was used to calculate the initial dose of methadone in all patients.
RESULTS: Mean pain scores decreased from 8.1 to 4.8 on Day 1 after the switch and to 3.22 on Day 4 after the switch. Mean sedation scores were 1.5 before the switch and 0.44 and 0.16 on Days 1 and 4, respectively. Among the 6 patients who experienced confusion while on fentanyl before the switch, 5 improved within 2 days of the switch. None of the patients experienced toxicity from methadone.
CONCLUSIONS: On the basis of this preliminary study, the authors suggest that when switching from intravenous fentanyl to methadone a conversion ratio of 25 microg/hour of fentanyl to 0.1 mg/hour of methadone may be safe and effective. Copyright 2001 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11745266     DOI: 10.1002/1097-0142(20011001)92:7<1919::aid-cncr1710>3.0.co;2-g

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

1.  Long-term low-dose morphine for patients with moderate cancer pain is predominant factor effecting clinically meaningful pain reduction.

Authors:  Ru-Jun Zheng; Yan Fu; Jiang Zhu; Jiu-Ping Xu; Qiu-Fen Xiang; Lin Chen; Hua Zhong; Jun-Ying Li; Chun-Hua Yu
Journal:  Support Care Cancer       Date:  2018-05-31       Impact factor: 3.603

2.  Methadone patient-controlled analgesia for postoperative pain: a randomized, controlled, double-blind study.

Authors:  José Osvaldo Barbosa Neto; Maria Deneb Tavares Machado; Marta de Almeida Correa; Hamilton Alves Scomparim; Irimar Paula Posso; Hazem Adel Ashmawi
Journal:  J Anesth       Date:  2014-01-21       Impact factor: 2.078

3.  [Opioids for cancer pain treatment. Efficacy and side effects].

Authors:  E Klaschik; K E Clemens
Journal:  Schmerz       Date:  2005-10       Impact factor: 1.107

4.  Dose calculation in opioid rotation: electronic calculator vs. manual calculation.

Authors:  Herbert Plagge; Wilhelm Ruppen; Norman Ott; Thomas Fabbro; Delia Bornand; Stefanie Deuster
Journal:  Int J Clin Pharm       Date:  2011-01-13

5.  Subcutaneous or intravenous opioid administration by patient-controlled analgesia in cancer pain: a systematic literature review.

Authors:  Lisa Nijland; Pia Schmidt; Michael Frosch; Julia Wager; Bettina Hübner-Möhler; Ross Drake; Boris Zernikow
Journal:  Support Care Cancer       Date:  2018-07-28       Impact factor: 3.603

6.  The successful use of parenteral methadone in a patient with a prolonged QTc interval.

Authors:  Ryuichi Sekine; Eugenie A M T Obbens; Nessa Coyle; Charles E Inturrisi
Journal:  J Pain Symptom Manage       Date:  2007-07-05       Impact factor: 3.612

7.  Efficacy of opioid rotation to continuous parenteral hydromorphone in advanced cancer patients failing on other opioids.

Authors:  Wendy H Oldenmenger; Paul J Lieverse; Paul J J M Janssen; Walter Taal; Carin C D van der Rijt; Agnes Jager
Journal:  Support Care Cancer       Date:  2011-08-23       Impact factor: 3.603

8.  Pain in methadone patients: Time to address undertreatment and suicide risk (ANRS-Methaville trial).

Authors:  Sandra Nordmann; Antoine Vilotitch; Caroline Lions; Laurent Michel; Marion Mora; Bruno Spire; Gwenaelle Maradan; Marc-Karim Bendiane; Alain Morel; Perrine Roux; Patrizia Carrieri
Journal:  PLoS One       Date:  2017-05-17       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.